|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kinoshita FL, Ito Y and Nakayama T: Trends
in lung cancer incidence rates by histological type in 1975-2008: A
population-based study in Osaka, Japan. J Epidemiol. 26:579–586.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Aoun-Bacha Z, Bitar N, Saleh WA, Assi H,
Bahous J, Boukhalil P, Chami H, Dabar G, El Karak F, Farhat F, et
al: Diagnosis and management of patients with stage III non-small
cell lung cancer: A joint statement by the Lebanese Society of
Medical Oncology and the Lebanese Pulmonary Society (Review). Oncol
Lett. 25(113)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Covington MF, Koppula BR, Fine GC, Salem
AE, Wiggins RH, Hoffman JM and Morton KA: PET-CT in Clinical Adult
Oncology: II. Primary Thoracic and Breast Malignancies. Cancers
(Basel). 14(2689)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Balata H, Fong KM, Hendriks LE, Lam S,
Ostroff JS, Peled N, Wu N and Aggarwal C: Prevention and early
detection for NSCLC: Advances in thoracic oncology 2018. J Thorac
Oncol. 14:1513–1527. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Daly ME, Singh N, Ismaila N, Antonoff MB,
Arenberg DA, Bradley J, David E, Detterbeck F, Früh M, Gubens MA,
et al: Management of Stage III Non-Small-Cell Lung Cancer: ASCO
Guideline. J Clin Oncol. 40:1356–1384. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Simone CB II, Bradley J, Chen AB, Daly ME,
Louie AV, Robinson CG, Videtic GMM and Rodrigues G: ASTRO radiation
therapy summary of the ASCO guideline on management of stage III
non-small cell lung cancer. Pract Radiat Oncol. 13:195–202.
2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bradley JD, Paulus R, Komaki R, Masters G,
Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A,
et al: Standard-dose versus high-dose conformal radiotherapy with
concurrent and consolidation carboplatin plus paclitaxel with or
without cetuximab for patients with stage IIIA or IIIB
non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two
factorial phase 3 study. Lancet Oncol. 16:187–199. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bradley JD, Hu C, Komaki RR, Masters GA,
Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM,
Kavadi VS, et al: Long-Term Results of NRG Oncology RTOG 0617:
Standard-versus high-dose chemoradiotherapy with or without
cetuximab for unresectable stage III non-small-cell lung cancer. J
Clin Oncol. 38:706–714. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Spigel DR, Faivre-Finn C, Gray JE, Vicente
D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R,
Quantin X, et al: Five-Year survival outcomes from the PACIFIC
Trial: Durvalumab after chemoradiotherapy in stage III
Non-Small-Cell Lung Cancer. J Clin Oncol. 40:1301–1311.
2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Palma DA, Senan S, Tsujino K, Barriger RB,
Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, et al:
Predicting radiation pneumonitis after chemoradiation therapy for
lung cancer: An international individual patient data
meta-analysis. Int J Radiat Oncol Biol Phys. 85:444–450.
2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
De Ruysscher D, Faivre-Finn C, Moeller D,
Nestle U, Hurkmans CW, Le Péchoux C, Belderbos J, Guckenberger M
and Senan S: Lung Group and the Radiation Oncology Group of the
European Organization for Research and Treatment of Cancer (EORTC).
European Organization for Research and Treatment of Cancer (EORTC)
recommendations for planning and delivery of high-dose, high
precision radiotherapy for lung cancer. Radiother Oncol. 124:1–10.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nestle U, De Ruysscher D, Ricardi U, Geets
X, Belderbos J, Pöttgen C, Dziadiuszko R, Peeters S, Lievens Y,
Hurkmans C, et al: ESTRO ACROP guidelines for target volume
definition in the treatment of locally advanced non-small cell lung
cancer. Radiother Oncol. 127:1–5. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Itazawa T, Tamaki Y, Komiyama T, Nishimura
Y, Nakayama Y, Ito H, Ohde Y, Kusumoto M, Sakai S, Suzuki K, et al:
The Japan Lung Cancer Society-Japanese Society for Radiation
Oncology consensus-based computed tomographic atlas for defining
regional lymph node stations in radiotherapy for lung cancer. J
Radiat Res. 58:86–105. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gospodarowicz MK, Wittekind C and Brierley
JD (eds): Lung. In: TNM Classification of Malignant Tumours. 8th
edition. Wiley-Blackwell, New Jersey, pp106-112, 2016.
|
|
16
|
Wang K, Eblan MJ, Deal AM, Lipner M, Zagar
TM, Wang Y, Mavroidis P, Lee CB, Jensen BC, Rosenman JG, et al:
Cardiac toxicity after radiotherapy for stage III non-small-cell
lung cancer: Pooled analysis of dose-escalation trials delivering
70 to 90 gy. J Clin Oncol. 35:1387–1394. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cui T, Zhang A, Cui J, Chen L, Chen G, Dai
H, Qin X, Li G and Sun J: Feasibility of omitting the clinical
target volume under PET-CT guidance in unresectable stage III
non-small-cell lung cancer: A phase II clinical trial. Radiother
Oncol. 181(109505)2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yuan S, Sun X, Li M, Yu J, Ren R, Yu Y, Li
J, Liu X, Wang R, Li B, et al: A randomized study of involved-field
irradiation versus elective nodal irradiation in combination with
concurrent chemotherapy for inoperable stage III nonsmall cell lung
cancer. Am J Clin Oncol. 30:239–244. 2007.PubMed/NCBI View Article : Google Scholar
|
